Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp139 | Paediatric Endocrinology & Development | ECE2016

2nd year efficacy results of once-weekly administration of CTP-modified human growth hormone (MOD-4023): a phase 2 study in children with growth hormone deficiency

Zelinska Nataliya , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G , Zadik Zvi , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili , Radziuk Klaudziya

Objective: Growth hormone (GH) replacement therapy currently requires daily injections. This may cause poor compliance, inconvenience and distress for patients. CTP-modified hGH (MOD-4023) has been developed for once-weekly administration in growth hormone deficient (GHD) adults and children. The 18 and 24 month efficacy of once-weekly subcutaneous (SC) administration of MOD-4023 was evaluated in a Phase 2 study in children with GH deficiency.Design and ...

ea0041ep845 | Paediatric endocrinology | ECE2016

Safety and tolerability of once-weekly administration of CTP-modified human growth hormone (MOD-4023): phase 2 study in children with growth hormone deficiency

Zelinska Nataliya , Iotova Violeta , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G. , Zadik Zvi , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili , Radziuk Klaudziya

Objective: Growth hormone (GH) replacement therapy currently requires daily injections. This may cause poor compliance, inconvenience and distress for patients. CTP-modified human GH (MOD-4023) has been developed for once-weekly administration in growth hormone-deficient (GHD) adults and children. In the present Phase 2 study, the safety and tolerability of once-weekly subcutaneous (SC) administration of MOD-4023 were evaluated in GHD children.Design and...